药学学报, 2016, 51(9): 1378-1387
引用本文:
姜心贝, 李艳萍, 李卓荣. HCV NS5A抑制剂研究进展[J]. 药学学报, 2016, 51(9): 1378-1387.
JIANG Xin-bei, LI Yan-ping, LI Zhuo-rong. Research progress of HCV NS5A complex inhibitors[J]. Acta Pharmaceutica Sinica, 2016, 51(9): 1378-1387.

HCV NS5A抑制剂研究进展
姜心贝, 李艳萍, 李卓荣
中国医学科学院、北京协和医学院医药生物技术研究所, 北京 100050
摘要:
近年来抑制丙型肝炎病毒(HCV)复制的直接抗病毒药物得到了快速的发展,HCV非结构蛋白5A(NS5A)抑制剂由于抗病毒活性强、清除病毒快速和抗病毒谱广的特点成为了HCV抑制剂研究的新热点。本文综述了2010年以来有关HCV NS5A抑制剂研究的主要进展,并从化学结构角度出发,对不同化合物的药学特点进行分别阐述和归纳总结。
关键词:    丙型肝炎病毒      非结构蛋白5A      抑制剂      抗病毒     
Research progress of HCV NS5A complex inhibitors
JIANG Xin-bei, LI Yan-ping, LI Zhuo-rong
Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
Abstract:
Direct acting antivirals against the hepatitis C virus (HCV) have been developed and the field has been under a rapid progress in recent years. Especially, HCV inhibitors targeting nonstructural 5A (NS5A) protein are attracting much attention due to the potent antiviral activity, fast viral clearance and broad antiviral spectrum. This article is prepared to cover the main progress of HCV NS5A complex inhibitors in the market since 2010. The pharmaceutical characteristics of diverse compounds are described and summarized according to their different chemotypes.
Key words:    hepatitis C virus    nonstructural 5A protein    inhibitor    antiviral   
收稿日期: 2016-03-04
DOI: 10.16438/j.0513-4870.2016-0169
基金项目: 北京市自然科学基金资助项目(7132166)。
通讯作者: 李艳萍
Email: liyanping08@hotmail.com
相关功能
PDF(1250KB) Free
打印本文
0
作者相关文章
姜心贝  在本刊中的所有文章
李艳萍  在本刊中的所有文章
李卓荣  在本刊中的所有文章

参考文献:
[1] http://www.who.int/mediacentre/factsheets/fs164/en/.
[2] Lambert SM, Langley DR, Garnett JA, et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors [J]. Protein Sci, 2014, 23: 723-734.
[3] Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response [J]. J Virol, 2001, 75: 6095-6106.
[4] Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? [J]. Hepat Med, 2015: 711-720.
[5] Liu D, Ji J, Ndongwe TP, et al. Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach [J]. Antimicrob Agents Chemother, 2015, 59: 3482-3492.
[6] O'Boyle DR 2nd, Nower PT, Lemm JA, et al. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay [J]. Antimicrob Agents Chemother, 2005, 49: 1346-1353.
[7] Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect [J]. Nature, 2010, 465: 96-100.
[8] Belema M, Lopez OD, Bender JA, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors [J]. J Med Chem, 2014, 57: 1643-1672.
[9] Belema M, Nguyen VN, Bachand C, et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir [J]. J Med Chem, 2014, 57: 2013-2032.
[10] Belema M, Meanwell NA. Discovery of daclatasvir, a pan-genotypic hepatitis C virus NS5A [J]. J Med Chem, 2014, 57: 5057-5071.
[11] Love RA, Brodsky O, Hickey MJ, et al. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus [J]. J Virol, 2009, 83: 4395-4403.
[12] O'Boyle li DR, Sun JH, Nower PT, et al. Characterizations of HCV NS5A replication complex inhibitors [J]. Virology, 2013, 444: 343-354.
[13] Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection [J]. Hematology, 2014, 59: 2083-2091.
[14] Aghemo A, De Francesco R. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C [J]. Gut, 2015, 64: 6860-6862.
[15] Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 Phase III Study [J]. Hematology, 2015, 61: 1127-1135.
[16] Bachand C, Belema M, Deon DH, et al. Hepatitis C virus inhibitors: WO 2008021928 [P]. 2007-8-9.
[17] Ivachtchenko AV, Mitkin OD, Yamanushkin PM, et al. Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025) [J]. J Med Chem, 2014, 57: 7716-7730.
[18] Degoey DA, Randolph JT, Liu D, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A [J]. J Med Chem, 2014, 57: 2047-2057.
[19] Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial [J]. Lancet, 2015, 385: 2502-2509.
[20] http://allachem.com/allachem-llc-completes-phase-ibiia-clinical-study-with-av4025-an-hcv-ns5a-inhibitor/.
[21] Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity [J]. ChemMedChem, 2013, 8: 1930-1940.
[22] Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial [J]. Lancet Hiv, 2015, 2: 319-327.
[23] Lalezari JP, Farrell GC, Shah PS, et al. PPI-668, a potent new pan-genotypic HCV NS5A inhibitor: Phase 1 efficacy and safety [J]. Hematology, 2012, 56 (Suppl 1): 1065A-1066A.
[24] Lalezari J, Holland L, Glutzer E, et al. Rapid and consistent virologic responses in a phase 2 trial of a new all-oral combination of faldaprevir, deleobuvir and PPI-668, with and without ribavirin, in patients with HCV genotype-1a infection [J]. Hematology, 2013, 58 (Suppl 1): 1389A.
[25] Kazmierski WM, Maynard A, Duan MS, et al. Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound [J]. J Med Chem, 2014, 57: 2058-2073.
[26] Bechtel J, Crosby R, Wang A, et al. In vitro profiling of GSK2336805, a potent and selective inhibitor of HCV NS5A [J]. J Hepatol, 2011, 54 (Suppl 1): S307-S308.
[27] Wilfret DA, Walker J, Adkison KK, et al. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1 [J]. Antimicrob Agents Chemother, 2013, 57: 5037-5044.
[28] http://clinicaltrials.gov/ct2/show/NCT01648140.
[29] Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis c virus infection [J]. J Med Chem, 2014, 57: 2033-2046.
[30] Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection [J]. N Engl J Med, 2014, 370: 1483-1493.
[31] Bilello JP, Lallos LB, McCarville JF, et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus [J]. Antimicrob Agents Chemother, 2014, 58: 4431-4442.
[32] Vince B, Hill JM, Lawitz EJ, et al. A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patientsinfected with hepatitis C virus genotype 1, 2, 3 or 4 [J]. J Hepatol, 2014, 60: 920-927.
[33] Cheng G, Yu M, Peng B, et al. GS-5816, a second-generation HCV NS5A inhibitor with potent antiviral activity, broad genotypic coverage, and a high resistance barrier [J]. J Hepatol, 2013, 58 (Suppl 1): S484-S485.
[34] Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection [J]. N Engl J Med, 2015, 373: 2608-2617.
[35] Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection [J]. N Engl J Med, 2015, 373: 2599-2607.
[36] Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis [J]. N Engl J Med, 2015, 373: 2618-2628.
[37] Huang M, Yang G, Patel D, et al. ACH-2928: a novel high potent HCV NS5A inhibitor with favorable preclinical characteristics [J]. J Hepatol, 2013, 54 (Suppl 1): S479.
[38] Muir A, Hill J, Lawitz E, et al. ACH-3102, a second generation NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1a HCV infection despite the presence of baseline NS5A-resistant variants [J]. J Hepatol, 2013, 58 (Suppl 1): S360.
[39] Gane E, Schwabe C, Mader M, et al. Sustained virologic response after ACH-3102 and sofosbuvir treatment for 8 or 6 weeks: a phase 2 "Proxy" study [J]. J Hepatol, 2013, 58 (Suppl 1): S266.
[40] Teresa NG, Pilot-Matias TJ, Krishnan P, et al. Methods for treating hepatitis C: WO 2014047039 [P]. 2014-03-07.
[41] Teresa NG, Krishnan P, Kati W, et al. ABT-530, an HCV NS5A inhibitor with potent pangenotypic activity and high genetic barrier to resistance. 21st Annual Conference on Retroviruses and Opportunistic Infections (CROI) [C]. Boston, Massachusetts, United States, March 3-6, 2014.
[42] Poordad F, Felizarta F, Asatryan A, et al. 98%-100% SVR4 in HCV genotype 1 non-cirrhotic treatment-naive or pegylated interferon/ribavirin null responders with the combination of the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 (SURVEYOR-1) [J]. Hematology, 2015, 62 (Suppl 1): 228A-229A.
[43] Kwo PY, Bennett M, Wang S, et al. High SVR4 rates achieved with the next generation NS3/4A protease inhibitor ABT-493 and NS5A inhibitor ABT-530 in non-cirrhotic treatment-naive and treatment-experienced patients with HCV genotype 3 infection (SURVEYOR-2) [J]. Hematology, 2015, 65 (Suppl 1): 337A-338A.
[44] Wyles D, LSulkowski MS, Wang S, et al. Inhibitor ABT-530 in non-cirrhotic treatment-naive and treatment-experienced patients with HCV genotype 2 infection (SURVEYOR-2) [J]. Hematology, 2015, 65 (Suppl 1): 339A-340A.
[45] Giroux S, Xu J, Reddy TJ, et al. Discovery of thienoimida­zole-based HCV NS5A genotype 1a and 1b inhibitors [J]. ACS Med Chem Lett, 2013, 5: 240-243.
[46] Henderson JA, Bilimoria D, Bubenik M, et al. Benzimida­zole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency [J]. Bioorg Med Chem Lett, 2015, 25: 944-947.
[47] Henderson JA, Bilimoria D, Bubenik M, et al. Synthesis and evaluation of NS5A inhibitors containing diverse heteroaro­matic cores [J]. Bioorg Med Chem Lett, 2015, 25: 948-951.
[48] Koen V, Raboisson PJMB. Quinazolinone derivatives as HCV inhibitors: WO 2013098320 A1 [P]. 2013-07-04.
[49] Bianco A, Reghellin V, Donnici L, et al. Metabolism of phosphatidylinositol 4-kinase IIIa-dependent PI4P is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity [J]. PLoS Pathog, 2012, 8: e1002576.
[50] Makonen B, Lopez OD, Bender JA, et al. Discovery and development of hepatitis C virus NS5A replication complex inhibitors [J]. J Med Chem, 2014, 57: 1643-1672.
[51] Degoey DA, Betebenner DA, Grampovnik DJ, et al. Discovery of pyrido[2,3-d]pyrimidine-based inhibitors of HCV NS5A [J]. Bioorg Med Chem Lett, 2013, 23: 3627-3630.
[52] Wheelhouse CJ, Thomas AJF, Bushnell, et al. Biphenyl derivatives and their use in treating hepatitis C: WO 2007031791 [P]. 2006-9-18.
[53] Carter MC, Cockerill S, Flack SS, et al. Heterocylic deriva­tives and their use in treating hepatitis C: WO 2009034390 [P]. 2008-9-12.
[54] Carter MC, Mathews N. Novel biphenyl compounds useful for the treatment of hepatitis C: WO 2010094977 [P]. 2010-2-22.
[55] Conte I, Giuliano C, Ercolani C, et al. Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture [J]. Bioorg Med Chem Lett, 2009, 19: 1779-1783.
相关文献:
1.徐淑静, 刘新泳, 展鹏.呼吸道合胞病毒抑制剂研究新进展[J]. 药学学报, 2020,55(4): 597-610
2.修思雨, 张健, 鞠翰, 贾瑞芳, 黄兵, 展鹏, 刘新泳.抗流感病毒药物靶标及其小分子抑制剂的研究进展[J]. 药学学报, 2020,55(4): 611-626
3.宋淑, 高萍, 展鹏, 刘新泳.丙型肝炎病毒抑制剂研究进展[J]. 药学学报, 2020,55(4): 652-668
4.任玉洁, 张硕, 魏粉菊, 刘新泳, 展鹏.埃博拉病毒抑制剂研究新进展[J]. 药学学报, 2020,55(4): 694-702
5.姜向毅, 李敬, 魏晓颖, 展鹏, 刘新泳.基孔肯雅病毒抑制剂研究进展[J]. 药学学报, 2020,55(4): 754-762
6.王萍, 张高红, 向思颖, 杨柳萌, 唐成润, 马晓东, 郑永唐.二甲苯酮类非核苷类逆转录酶抑制剂的体外抗HIV-1活性[J]. 药学学报, 2016,51(11): 1704-1710
7.李文静, 李健蕊, 黄梦昊, 吴舟一, 陈金花, 李虎, 吕晓芹, 程军军, 彭宗根.细胞角蛋白8对丙型肝炎病毒复制的影响[J]. 药学学报, 2016,51(6): 913-918